Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Assets (2019 - 2025)

BridgeBio Pharma's Current Assets history spans 7 years, with the latest figure at $797.7 million for Q4 2025.

  • For Q4 2025, Current Assets rose 10.69% year-over-year to $797.7 million; the TTM value through Dec 2025 reached $797.7 million, up 10.69%, while the annual FY2025 figure was $797.7 million, 10.69% up from the prior year.
  • Current Assets for Q4 2025 was $797.7 million at BridgeBio Pharma, down from $839.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $945.1 million in Q1 2021 and bottomed at $432.9 million in Q2 2023.
  • The 5-year median for Current Assets is $705.7 million (2022), against an average of $696.1 million.
  • The largest annual shift saw Current Assets plummeted 43.87% in 2023 before it soared 88.8% in 2025.
  • A 5-year view of Current Assets shows it stood at $888.9 million in 2021, then plummeted by 38.25% to $548.9 million in 2022, then dropped by 12.98% to $477.6 million in 2023, then skyrocketed by 50.9% to $720.7 million in 2024, then rose by 10.69% to $797.7 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Current Assets are $797.7 million (Q4 2025), $839.4 million (Q3 2025), and $912.3 million (Q2 2025).